Pfizer Inc. (0Q1N.IL)
- Barrons.com
GSK Will Pay Up to $1.5 Billion for CureVac’s mRNA Vaccines
CureVac is also eligible for future royalties. CureVac shares jumped 12% in early trading Wednesday, while GSK’s American depositary receipt slipped 0.2%. Shares of Moderna a leading mRNA vaccine manufacturer, were up 0.9%.
- Zacks
Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
- Investor's Business Daily
Pfizer Hits 11-Year Low And Lingers Sideways For Months — Is It Now A Sell?
Pfizer[ticker symb=PFE] stock continues trending sideways after announcing promising updates for two cancer drugs, but also shutting down a gene therapy program. In one study, multiple myeloma patients who received Pfizer's Elrexfio lived for 24.6 months, at the median. Another study tested Adcetris against chemotherapy in patients with a form of lymphoma.
